Impact of Guideline-Based Medical Therapy on Malignant Arrhythmias and
Mortality among Heart Failure Patients Implanted with Cardioverter
Defibrillator (ICD) or Cardiac Resynchronization-Defibrillator device
(CRTD)
Tal Hasin, MD,1,2 Ilia Davarashvili,
MD,1 Yoav Michowitz, MD,1 Rivka
Farkash, MPH, 1 Haya Presman,2Michael Glikson, MD,1 Moshe Rav-Acha,
MD1
1 Jesselson integrated heart center, Shaare Zedek
medical center; Hebrew University, Jerusalem, Israel
2 Faculty of Medicine, Hebrew University, Jerusalem
Israel
Short title: Importance of HF treatment among defibrillator implantees
Authors address:
Tal Hasin: hasint@szmc.org.il
Ilia Davarashvili: ilyad@szmc.org.il
Yoav Michowitz: yoavm@szmc.org.il
Rivka Farkash: rivka_f@szmc.org.il
Haya Presman: Haya.presman@mail.huji.ac.il
Michael Glikson: mglikson@szmc.org.il
Moshe Rav-Acha: ravacham@szmc.org.il
* All work done at share Zedek Hospital, Jerusalem
Corresponding author:
Dr Moshe Rav Acha
Cardiology dept. Shaare Zedek hospital
Shmuel Biet 4, Jerusalem, Israel
972-84005155
ravacham@szmc.org.il